Neos Therapeutics
AcquiredGrand Prairie, US · Founded 2009 · Delaware corporation · 1 known investors
Find your way into Neos Therapeutics
130 people in our graph share verified history with the Neos Therapeutics team — schools, employers, funds. One of them is your warm intro.
Paul Osmundsonunlockedknows Mark Tengler · together at Colorado State University (overlapped)
×11knows the team · via Colorado State University
Acquired by Aytu BioScience (later Aytu BioPharma) December 2020 · $44.9M ($44.9 million all-stock deal) · source ↗
Neos Therapeutics was a pharmaceutical company developing and commercializing ADHD treatments, including the branded dissolvable medications Adzenys and Cotempla.
Founders & leadership
SL
Steven LutzVP Sales
CS
Carolyn SikesVP Clinical Affairs
RM
Russ McMahenVP Research and Development
MC
Margaret CabanoVP Operations
RE
Richard EisenstadtinChief Financial Officer and Secretary
AM
Asif MughalVP Quality Assurance
MT
Mark TenglerinFounder (out of the Pharmafab ashes), Principal Inventor and President2006–2009He has experience in the pharmaceuticals industry with expertise in FDA regulation, biotechnology, chemistry, and GMP processes.
VM
Victor MillerVP Finance
VG
Vipin GargChief Executive Officer
EH
Ellen HoffingCo-President and Chief Operating Officer
Board
GR
Greg RobitailleBoard director
RI
Ralph IannelliBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$38.6M disclosed across 3 rounds · 2013–2014
▶$20.6MraisedFeb 2015 · 27 investors · PharmaceuticalsRule 506(b)
▶$20.6MraisedFeb 2015 · 27 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven LutzExecutive Officer
- Carolyn SikesExecutive Officer
- Arlen EwartExecutive Officer
- Russ McMahenExecutive Officer
- Stacie SwitzerExecutive Officer
- Margaret CabanoExecutive Officer
- Greg RobitailleDirector
- Richard EisenstadtExecutive Officer
- Alan HellerDirector
- Asif MughalExecutive Officer
- Mark TenglerExecutive Officer
- Ralph IannelliDirector
- Vipin GargExecutive Officer, Director
- Bryant FongDirector
- Edward SchnipperDirector
- Dorothy EngelkingExecutive Officer
- Offering amount
- $20.6M
- Amount sold
- $20.6M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedApr 2014 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedApr 2014 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark TenglerExecutive Officer
- Alan HellerDirector
- Greg RobitailleDirector
- Russ McMahenExecutive Officer
- Asif MughalExecutive Officer
- Bryant FongDirector
- Dorothy EngelkingExecutive Officer
- Stacie SwitzerExecutive Officer
- Arlen EwartExecutive Officer
- Ralph IannelliDirector
- Edward SchnipperDirector
- Vipin GargDirector
- Margaret CabanoExecutive Officer
- Carolyn SikesExecutive Officer
- Victor MillerExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
▶$15.5MraisedMar 2014 · 25 investors · PharmaceuticalsRule 506(b)
▶$15.5MraisedMar 2014 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Asif MughalExecutive Officer
- Bryant FongDirector
- Greg RobitailleDirector
- Victor MillerExecutive Officer
- Carolyn SikesExecutive Officer
- Alan HellerDirector
- Margaret CabanoExecutive Officer
- Vipin GargDirector
- Stacie SwitzerExecutive Officer
- Ralph IannelliDirector
- Ellen HoffingExecutive Officer
- Arlen EwartExecutive Officer
- Dorothy EngelkingExecutive Officer
- Mark TenglerExecutive Officer
- Russ McMahenExecutive Officer
- Edward SchnipperDirector
- Offering amount
- $15.5M
- Amount sold
- $15.5M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Neos Therapeutics do?
- Neos Therapeutics was a pharmaceutical company developing and commercializing ADHD treatments, including the branded dissolvable medications Adzenys and Cotempla.
- Who are Neos Therapeutics's investors?
- Neos Therapeutics's investors include Sofinnova Ventures.
- How much funding has Neos Therapeutics raised?
- Neos Therapeutics has disclosed $38.6M raised across 3 rounds.
- Where is Neos Therapeutics headquartered?
- Neos Therapeutics is headquartered in Grand Prairie, US.